GALT Galectin Therapeutics
- 1.040
- -0.960-48.00%
- 1.020
- -0.020-1.92%
Galectin Therapeutics News
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11
Galectin Therapeutics Analyst Ratings
Optimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost Prospects
Buy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and With Strong Cash Position
Galectin Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)
Galectin Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Buy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial Stability
Galectin Therapeutics Analyst Ratings
Arce's Buy Rating on Galectin Therapeutics: Promising NAVIGATE Trial Progress and Strong Financial Outlook
Galectin Therapeutics Analyst Ratings
H.C. Wainwright Remains a Buy on Galectin Therapeutics (GALT)
Analysts' Top Healthcare Picks: Galectin Therapeutics (GALT), Cabaletta Bio (CABA)
H.C. Wainwright Sticks to Their Buy Rating for Galectin Therapeutics (GALT)
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
H.C. Wainwright Sticks to Its Buy Rating for Galectin Therapeutics (GALT)
H.C. Wainwright Sticks to Their Buy Rating for Galectin Therapeutics (GALT)
Analysts Are Bullish on Top Healthcare Stocks: Galectin Therapeutics (GALT), Viridian Therapeutics (VRDN)
H.C. Wainwright Sticks to Its Buy Rating for Galectin Therapeutics (GALT)
No Data